<DOC>
	<DOCNO>NCT00692510</DOCNO>
	<brief_summary>The purpose study evaluate AZD3480 inhibit Cytochrome P450 1A2 , 2C19 , 3A4 , 2C8 , 2B6 UGT1A1 activity .</brief_summary>
	<brief_title>Drug Interaction Study Between AZD3480 Cytochrome P450</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>Provision sign write informed consent Clinically normal physical finding laboratory value Clinically significant illness clinically relevant trauma within three week first dose History clinically significant disease Use prescribe medication 2 week administration first dose investigational product</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>AZD3480</keyword>
	<keyword>Cocktail</keyword>
	<keyword>caffeine</keyword>
	<keyword>bupropion</keyword>
	<keyword>omeprazole</keyword>
	<keyword>midazolam</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>metabolism</keyword>
	<keyword>Drug Drug Interaction</keyword>
</DOC>